Since the emergence of the COVID-19 pandemic, there has been increased interest in developing a universal antiviral that would stop a pandemic in its tracks.
AstraZeneca and Sanofi’s Phase III and Phase IIb clinical trials investigating the efficacy of nirsevimab, measured through the development of secondary infections, are impressing the pharma community with positive prespecified pooled analysis results. The data shows 79.5 percent efficacy in the prevention of lower respiratory tract infections, caused by infection of the respiratory syncytial virus (RSV).
Pfizer boosts respiratory drug portfolio with ReViral purchase April 7, 2022 By Bhanvi Satija April 7 (Reuters) – Pfizer Inc (PFE.N) said on Thursday it would buy privately-held ReViral Ltd in a deal worth as much as $525 million including milestone payments, to gain access to experimental drugs against the respiratory syncytial virus (RSV). The […]
Pfizer announced March 24 that the company received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the vaccine candidate PF-06928316 (RSVpreF), intended to prevent infections caused by a respiratory syncytial virus (RSV).
Moderna is broadening the company’s vaccine horizons once again using mRNA technology, widely known for its use in COVID-19 vaccinations. Moderna announced two new vaccine development programs targeting a variety of viruses.
The latest results from Sanofi and AstraZeneca’s Phase III trial for nirsevimab demonstrate the vaccine’s ability to protect all infants from the respiratory syncytial virus (RSV) with a single dose.
Britain’s GSK halted enrollment and vaccination in three trials of the company’s experimental vaccine against the respiratory syncytial virus (RSV) in pregnant women, the latest setback in developing a vaccine for the microbe.
Moderna Inc. has begun a late-stage study of a vaccine for respiratory syncytial virus (RSV) based on the same technology used to develop the company’s COVID-19 shots.
GSK paused a late-stage trial of the company’s vaccine candidate against the respiratory syncytial virus (RSV) in pregnant women based on safety recommendations from an independent committee, the British drugmaker said on February 18.
Britain’s GSK forecast growth in 2022 after racking up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, beating quarterly forecasts in the company’s first earnings report since rejecting Unilever’s bid for GlaxoSmithKline’s consumer arm.